000 | 01964 a2200589 4500 | ||
---|---|---|---|
005 | 20250517214026.0 | ||
264 | 0 | _c20190227 | |
008 | 201902s 0 0 eng d | ||
022 | _a1878-3686 | ||
024 | 7 |
_a10.1016/j.ccell.2018.04.001 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHellmann, Matthew D | |
245 | 0 | 0 |
_aTumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. _h[electronic resource] |
260 |
_bCancer cell _c05 2018 |
||
300 |
_a853-861.e4 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIpilimumab _xadministration & dosage |
650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMutation |
650 | 0 | 4 |
_aNivolumab _xadministration & dosage |
650 | 0 | 4 |
_aSmall Cell Lung Carcinoma _xdrug therapy |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTumor Burden _xdrug effects |
650 | 0 | 4 | _aExome Sequencing |
700 | 1 | _aCallahan, Margaret K | |
700 | 1 | _aAwad, Mark M | |
700 | 1 | _aCalvo, Emiliano | |
700 | 1 | _aAscierto, Paolo A | |
700 | 1 | _aAtmaca, Akin | |
700 | 1 | _aRizvi, Naiyer A | |
700 | 1 | _aHirsch, Fred R | |
700 | 1 | _aSelvaggi, Giovanni | |
700 | 1 | _aSzustakowski, Joseph D | |
700 | 1 | _aSasson, Ariella | |
700 | 1 | _aGolhar, Ryan | |
700 | 1 | _aVitazka, Patrik | |
700 | 1 | _aChang, Han | |
700 | 1 | _aGeese, William J | |
700 | 1 | _aAntonia, Scott J | |
773 | 0 |
_tCancer cell _gvol. 33 _gno. 5 _gp. 853-861.e4 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ccell.2018.04.001 _zAvailable from publisher's website |
999 |
_c28361964 _d28361964 |